Alpha Cognition Inc
ACOG
株式のランク
#20037
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
株価
$8.56
時価総額
$132.95M
変化（1日）
0.71%
変化（1年）
70.18%
国
US
取引 Alpha Cognition Inc (ACOG)
カテゴリー
Healthcare
Alpha Cognition Inc（ACOG）の発行済株式数
June 2026 時点の発行済株式数 21.77M
Alpha Cognition Inc の最新の財務報告および株価によると、現在の発行済株式数は 21.77M です。December 2022 の終わりには、同社は 67.97M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Alpha Cognition Inc（ACOG）の発行済株式数の履歴（2018 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 21.77M | -76.92% |
| 2023 | 94.36M | 38.81% |
| 2022 | 67.97M | 27.45% |
| 2021 | 53.33M | 786.67% |
| 2020 | 6.02M | -80.88% |
| 2019 | 31.46M | 2,539.28% |
| 2018 | 1.19M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 1,066.06% |
US
|
|
| 396.00M | 1,718.67% |
US
|
|
| 478.91M | 2,099.46% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 185.59% |
NL
|
